Reported 1 day ago
Despite a significant market decline caused by tariffs announced by the Trump administration, pharmaceutical and biotech stocks saw relatively modest losses. Notably, some companies like Amgen and AstraZeneca even experienced gains. The sector benefitted from a temporary exemption from tariffs on pharmaceutical manufacturers, although future tariffs may still pose a threat. Positive news also emerged, such as the FDA's expansion of approval for Amgen's drug Uplizna, indicating the ongoing potential for innovation in these fields.
Source: YAHOO